Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-cash Items (2022 - 2025)

Taysha Gene Therapies' Non-cash Items history spans 4 years, with the latest figure at $300000.0 for Q3 2025.

  • For Q3 2025, Non-cash Items fell 70.0% year-over-year to $300000.0; the TTM value through Sep 2025 reached $300000.0, down 70.0%, while the annual FY2024 figure was $2.0 million, 0.36% changed from the prior year.
  • Non-cash Items for Q3 2025 was $300000.0 at Taysha Gene Therapies, down from $11.8 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $29.2 million in Q3 2022 and bottomed at $62000.0 in Q4 2022.
  • The 4-year median for Non-cash Items is $2.0 million (2023), against an average of $6.4 million.
  • The largest annual shift saw Non-cash Items soared 12723.53% in 2023 before it crashed 95.8% in 2025.
  • A 4-year view of Non-cash Items shows it stood at $62000.0 in 2022, then surged by 3061.29% to $2.0 million in 2023, then rose by 0.36% to $2.0 million in 2024, then crashed by 84.75% to $300000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Non-cash Items are $300000.0 (Q3 2025), $11.8 million (Q2 2025), and $600000.0 (Q1 2025).